Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2019

Open Access 01-12-2019 | Migraine | Research article

CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA

Authors: R. Moreno-Mayordomo, M. Ruiz, J. Pascual, M. Gallego de la Sacristana, I. Vidriales, M. Sobrado, E. Cernuda-Morollon, A. B. Gago-Veiga, D. Garcia-Azorin, J. J. Telleria, A. L. Guerrero

Published in: The Journal of Headache and Pain | Issue 1/2019

Login to get access

Abstract

Background

Some variables have been proposed as predictors of efficacy of OnabotulinumtoxinA in chronic migraine patients, but data available are inconclusive. We aimed to analyse the influence of single nucleotide polymorphisms in the response to OnabotulinumtoxinA.

Methods

We included 156 female patients treated with OnabotulinumtoxinA accordingly to PREEMPT paradigm in three headache units. OnabotulinumtoxinA was offered to patients that had not responded to topiramate and at least one other preventative. Age at first procedure was 43.7 ± 11.8 years (16–74). Patients with a reduction of at least 50% in the number of migraine days after two OnabotulinumtoxinA procedures were considered as responders. We analysed 25 polymorphisms selected for their relevance regarding migraine pathophysiology and their association with migraine according to previously published genome-wide association studies. Genotyping was performed using KASP probes and a LightCycler-480 (Roche-Diagnostics). Allelic, genotypic frequencies and dominance/recesivity hypothesis of the allelic variants were compared between responders and non-responders by Fisher’s exact test.

Results

Response to treatment with OnabotulinumtoxinA was achieved in 120 patients (76,9%). Two polymorphisms showed differences: CALCA rs3781719, where allele C represents 26.9% in responders and 40.9% in non-responders (p = 0.007, OR = 3.11 (1.33–7.26)); and TRPV1 rs222749, where allele A represents 4.17% in responders and 12.5% in non-responders (p = 0.013, OR = 3.29 (1.28–8.43)). No significant differences in rest of polymorphisms or clinical or demographic variables were found.

Conclusions

Polymorphic variations of CALCA and TRPV1 genes might play a role as prognostic markers of efficacy of OnabotulinumtoxinA in chronic migraine female patients in our population.
Appendix
Available only for authorised users
Literature
1.
May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464CrossRef
2.
Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803CrossRef
3.
Diener HC, Dodick DW, Aurora SK, Turkel CC, Degryse RE, Rb L et al (2010) Onabotulinumtoxin a for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814CrossRef
4.
Aurora SK, Winner P, Freeman MC, Turkel CC, Re DG, Silberstein SD et al (2011) OnabotulinumtoxinA form treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358–1373CrossRef
5.
Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P et al (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European headache federation. J Headache Pain 19(1)
6.
Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G et al (2017) Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia 37(14):1384–1397CrossRef
7.
Pedraza MI, De la Cruz C, Ruiz M, López-Mesonero L, Martínez E, de Lera M et al (2015) OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springer Plus 4:176CrossRef
8.
Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J (2015) Long-term experience with OnabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia 35:864–868CrossRef
9.
Negro A, Curto M, Lionetto L, Martelletti P (2016) A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain 17(1)
10.
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A (2018) Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine. J Headache Pain 19(1):13CrossRef
11.
Aicua I, Martínez E, Rojo A, Hernando A, Ruiz M, Carreres A et al (2016) Real-life data in 115 chronic migraine patients treated with OnabotulinumtoxinA during more than one year. J Headache Pain 17:112CrossRef
12.
Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE (2008) Botulinum toxin type a inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 101:366–370CrossRef
13.
Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 107:125–133CrossRef
14.
Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H et al (2012) Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-a. Neurobiol Dis 48:367–378CrossRef
15.
Aurora SK, Brin MF (2017) Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache 57:109–125CrossRef
16.
Johnson MP, Fernandez F, Colson NJ, Griffiths LR (2007) A pharmacogenomic evaluation of migraine therapy. Expert Opin Pharmacother 8:1821–1835CrossRef
17.
Sutherland HG, Buteri J (2013) Association study of the calcitonin gene-related polypeptide-alpha (CALCA) and the receptor activity modifying 1 (RAMP1) genes with migraine. Gene 515:187–192CrossRef
18.
Meents JE, Hoffmann J (2015) Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. J Headache Pain 16:57CrossRef
19.
Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type a in chronic migraine. Headache 54:987–995CrossRef
20.
Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C et al (2018) OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol 25(2):411–416CrossRef
21.
Hubbard CS, Becerra L, Smith JH, DeLange JM, Smith RM, Black DF et al (2016) Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal. Front Hum Neurosci 10:497CrossRef
22.
Pagola I, Esteve-Belloch P, Palma JA, Luquin MR, Riverol M, Martinez-Vila E et al (2014) Predictive factors of the response to treatment with Onabotulinumtoxin a in refractory migraine. Rev Neurol 58:241–246PubMed
23.
Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
24.
Chasman DI, Schürks M, Anttila V (2011) Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 43:695–698CrossRef
25.
Di Lorenzo C, Grieco GS, Santorelli FM (2012) Migraine headache: a review of the molecular genetics of a common disorder. J Headache Pain 13:571–580CrossRef
26.
Freilinger T, Anttila V, De VB, Malik R, Kallela M, Terwindt GM et al (2012) Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat Genet 15:777–782CrossRef
27.
Schürks M (2012) Genetics of migraine in the age of genome-wide association studies. J Headache Pain 13:1–9CrossRef
28.
Carreño O, Corominas R (2012) SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 159:94–103CrossRef
29.
Noch EK, Khalili K (2013) The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease. Adv Cancer Res 120:159–192CrossRef
30.
Quintas M, Neto JL (2013) Interaction between γ-aminobutyric acid a receptor genes: new evidence in migraine susceptibility. PLoS One 8:e74087CrossRef
31.
Ran C, Graae L, Magnusson PK, Pedersen NL (2014) A replication study of GWAS findings in migraine identifies association in a Swedish case-control sample. BMC Med Genet 28(15):38CrossRef
32.
Nyholt DR, LaForge KS (2008) A high-density association screen of 155 ion transport genes for involvement with common migraine. Hum Mol Genet 17:3318–3331CrossRef
33.
34.
Gentile G, Borro M, Simmaco M, Missori S, Lala N, Martelletti P (2011) Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug MetabToxicol 7:39–47CrossRef
35.
Cargnin S, Magnani F, Viana M, Tassorelli C, Mittino D, Cantello R et al (2013) An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans. J Pain 14:1097–1106CrossRef
36.
Ishii M, Sakairi Y, Hara H, Imagawa A, Shimizu S, Takahashi J et al (2012) Negative predictors of clinical response to triptans in patients with migraine. NeurolSci 33:453–461
37.
Terrazzino S, Viana M, Floriddia E, Monaco F, Mittino D, Sances G et al (2010) The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol 641:82–87CrossRef
38.
Di Lorenzo C, Pierelli F, Coppola G, Grieco GS, Rengo C, Ciccolella M et al (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72:1588–1594CrossRef
39.
Colhoun HM, McKeigue PM, Smith GD (2003) Problems of reporting genetic associations with complex outcomes. Lancet 361:865–872CrossRef
40.
Hattersley AT, McCarthy MI (2005) What makes a good genetic association study? Lancet. 366:1315–1323CrossRef
41.
Pompanon F, Bonin A, Bellemain E, Taberlet P (2005) Genotyping errors: causes, consequences and solutions. Nat Rev Genet 6:847–859CrossRef
42.
Maleki N, Linnman C, Brawn J, Burnstein R, Becerra L, Borsook D (2012) Her versus his migraine: multiple sex differences in brain function and structure. Brain 135:2546–2559CrossRef
43.
Marwaha L, Bansal Y, Singh R, Saroj P, Bhandari R, Kuhad A (2016) TRP channels: potential drug target for neuropathic pain. Inflammopharmacology 24:305–317CrossRef
44.
Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158:543–559CrossRef
45.
Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191–1196CrossRef
46.
Riesco N, Cernuda-Morollón E, Pascual J (2017) Neuropeptides as a marker for chronic headache. Curr Pain Headache Rep 21:18CrossRef
47.
Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J (2015) OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156:820–824CrossRef
48.
Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A et al (2018) CGRP and PTX3 as predictors of efficacy of OnabotulinumtoxinA type a in chronic migraine: an observational study. Headache 58(1):78–87CrossRef
49.
Zhang X, Strassman AM, Novack V, Brin MF, Burnstein R (2016) Extracranial injections of botulinum neurotoxin type a inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia 36:875–886CrossRef
Metadata
Title
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
Authors
R. Moreno-Mayordomo
M. Ruiz
J. Pascual
M. Gallego de la Sacristana
I. Vidriales
M. Sobrado
E. Cernuda-Morollon
A. B. Gago-Veiga
D. Garcia-Azorin
J. J. Telleria
A. L. Guerrero
Publication date
01-12-2019
Publisher
Springer Milan
Keyword
Migraine
Published in
The Journal of Headache and Pain / Issue 1/2019
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-019-0989-9

Other articles of this Issue 1/2019

The Journal of Headache and Pain 1/2019 Go to the issue

Research article

Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys

Research article

Migraine patients’ journey until a tertiary headache center: an observational study

Review article

Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications

Research article

Favourable prognosis of trigeminal neuralgia when enrolled in a multidisciplinary management program - a two-year prospective real-life study

Research article

Impaired intrinsic functional connectivity between the thalamus and visual cortex in migraine without aura

Research article

Development of an education and self-management intervention for chronic headache – CHESS trial (Chronic Headache Education and Self-management Study)